HomeFileStructural heart disease

Structural heart disease

Coronary Events after TAVI according to the FRANCE Registry

Between 30% and 70% of patients undergoing transcatheter aortic valve replacement (TAVR) present with coronary artery disease...

Should Early Aortic Valve Replacement Be Indicated in Asymptomatic Severe Aortic Stenosis?

A Meta-Analysis of Randomized Clinical Trials. The management of aortic stenosis in asymptomatic patients remains a matter of...

Predilatation in Self-Expanding Valves

TAVI has become the treatment of choice in specific scenarios. However, predilatation (PRD) remains a matter of...

Tricuspid Regurgitation, TriBicaval Registry

Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery...

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it...

ESC 2025 | DOUBLE-CHOICE: Anesthesia Strategies and Self-Expanding Valves in TAVI

TAVI has become the predominant treatment for severe aortic stenosis. The DOUBLE-CHOICE trial analyzed two key aspects:...

Can Colchicine Reduce Post-TAVR Conduction Disturbances?

Courtesy of Dr. Juan Manuel Pérez. Partly caused by perioperative inflammation, conduction disturbances often follow TAVR. Colchicine, known...

8 Questions About Left Atrial Appendage Closure: Contributions from the 2025 SCAI/HRS Review

Courtesy of Dr. Juan Manuel Pérez. Percutaneous left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation...